<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573376</url>
  </required_header>
  <id_info>
    <org_study_id>15-0809</org_study_id>
    <secondary_id>1R01DA040499-01</secondary_id>
    <nct_id>NCT02573376</nct_id>
  </id_info>
  <brief_title>Antiviral Pharmacology and Adherence in Drug Users</brief_title>
  <official_title>Antiviral Pharmacology and Adherence in Drug Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Denver Health and Hospital Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately one half of all Americans living with Hepatitis C virus (HCV) are drug users,&#xD;
      yet they are the least likely to receive HCV treatment. Drug users are presumed non-adherent&#xD;
      and therefore denied potentially life-saving therapy. This assumption can only be confirmed&#xD;
      or dispelled through prospective pharmacologic and adherence studies in this population. Such&#xD;
      studies would be greatly enhanced by an objective, quantitative measure of adherence which&#xD;
      does not currently exist in the HCV field. Through the work proposed in this application,&#xD;
      sixty HIV/HCV co-infected drug users will be treated with direct acting antiviral agents&#xD;
      (DAA) and randomized to receive directly observed DAA therapy (DOT) vs. no directly observed&#xD;
      therapy (no-DOT). Patients randomized to no-DOT will have wirelessly observed therapy (WOT)&#xD;
      which involves use of a portable medication dispenser that sends a signal to a server with&#xD;
      the date and time when the dispenser is opened. In Aim 1, DAA concentrations will be compared&#xD;
      in those randomized to DOT vs. no-DOT. DAA pharmacokinetics will also be defined accounting&#xD;
      for clinical factors like degree of hepatic impairment and use of concomitant recreational&#xD;
      and antiretroviral drugs. The goal is to quantify adherence in this population and the effect&#xD;
      of variable adherence on drug concentrations. In Aim 2, DAA concentrations (plasma, cellular,&#xD;
      hair) will be linked with adherence patterns identified using WOT and DOT. The goal is to&#xD;
      identify a drug concentration biomarker that predicts adherence in this population. In Aim 3,&#xD;
      the relationship between DAA adherence (as measured by WOT and DOT and drug concentrations)&#xD;
      and rate of cure will be established. The goal is to define the degree of adherence needed&#xD;
      for HCV cure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare each individual's modeled estimate of ledipasvir and metabolites of sofosbuvir (GS-331007 and GS-331007-TP) steady state concentrations (Css) from non-linear mixed effects modeling to Css in subjects receiving DOT vs. WOT.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantify GS-331007-TP concentrations in dried blood spots as a function of adherence (doses taken/doses prescribed).</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the probability of HCV cure as a function of adherence using logistic regression.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HEPATITIS C</condition>
  <condition>Virus, Human Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir/Ledipasvir with Directly Observed Therapy (DOT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants randomized to vDOT will be provided a smart phone with cellular service and will be pre-programmed with the mobile phone-based video application and contact information for study personnel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir/Ledipasvir with Wirelessly Observed Therapy (WOT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants on WOT will be provided the Wisepill portable medication dispenser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Directly Observed Therapy</intervention_name>
    <arm_group_label>Sofosbuvir/Ledipasvir with Directly Observed Therapy (DOT)</arm_group_label>
    <other_name>DOT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Wirelessly Observed Therapy</intervention_name>
    <arm_group_label>Sofosbuvir/Ledipasvir with Wirelessly Observed Therapy (WOT)</arm_group_label>
    <other_name>WOT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  HIV-infected men and women&#xD;
&#xD;
          -  Chronic HCV infection as documented by quantifiable HCV RNA&#xD;
&#xD;
          -  HCV genotype 1, 4, 5, 6&#xD;
&#xD;
          -  18-70 years of age&#xD;
&#xD;
          -  Willingness and ability to comply with study procedures, including DOT, WOT, and&#xD;
             biweekly clinic visits&#xD;
&#xD;
          -  Considered an active drug user by HCV provider and self-reported drug use within the&#xD;
             past month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Glomerular filtration rate &lt; 30 mL/min/1.73 m2&#xD;
&#xD;
          -  Receipt of prior HCV treatment and radiographic, histologic, or clinical evidence of&#xD;
             cirrhosis&#xD;
&#xD;
          -  Decompensated liver disease (i.e., ascites, history of esophageal variceal bleeding,&#xD;
             hepatic encephalopathy)&#xD;
&#xD;
          -  Medications not recommended per the SOF/LDV prescribing information (e.g., tipranavir&#xD;
             and other P-gp inducers, tenofovir disoproxil fumarate plus cobicistat, rosuvastatin,&#xD;
             amiodarone)&#xD;
&#xD;
          -  Any medical condition that in the opinion of the investigators will make it&#xD;
             challenging to adhere to the study protocol, such as unstable heart disease or cancer&#xD;
&#xD;
          -  Chronic Hepatitis B virus Infection&#xD;
&#xD;
          -  For females, active pregnancy or any intent to become pregnant&#xD;
&#xD;
          -  For both sexes, an unwillingness to use contraception during the study period&#xD;
&#xD;
          -  On parole or impending sentencing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer J Kiser, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Drug Abuse</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>sofosbuvir</keyword>
  <keyword>ledipasvir</keyword>
  <keyword>pharmacology</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

